Knobbe Martens
William Blandon has extensive work experience in finance and advisory roles. William is currently serving as the Chief Financial Officer at Knobbe Martens since July 2022. Prior to this, they worked at Armanino LLP from 2018 to 2022, holding positions such as Director, Law Firm Advisory Services and Senior Manager, Law Firm Advisory Services. Before joining Armanino LLP, they were employed at Gibson, Dunn & Crutcher LLP as a Manager, Financial Reporting from 2011 to 2018. William started their career at David Taussig & Associates, Inc. as a Senior Associate from 2005 to 2011.
William Blandon attended Loyola Marymount University from 2001 to 2005, where they completed a Bachelor of Business Administration (B.B.A.) degree with a focus on Finance.
This person is not in any teams
Knobbe Martens
2 followers
Our firm boasts IP law’s largest and most experienced biotechnology group, with more than 60 attorneys and scientists representing clients in all stages of their business and technology development. Our clients are innovators in a variety of disciplines including PCR, molecular tools and probes, immunology (antibodies and other binding proteins), cell varieties and uses (including stem cells) and biological polymers, to name but a few. Our expertise across the entire biotech landscape gives us great insight into specific technologies, systems and markets. More importantly, our holistic understanding of the interrelated technologies and systems typically involved in a single invention allows us to provide coordinated guidance and counsel from inception though introduction. Working in collaboration with more than 300 IP firms worldwide, we effect patent, trademark, copyright, and other filings, and direct oppositions, cancellations, and litigation matters in over 120 countries. We have considerable experience in negotiating and drafting traditional licensing agreements as well as agreements for strategic alliances, partnerships and joint ventures. We also maintain a talented litigation department adept in all aspects of biotechnology IP law, including the Biosimilars legislation. Our extensive Hatch-Waxman litigation experience combined with our understanding of the biotechnology industry uniquely positions Knobbe Martens to help clients develop and implement litigation strategies designed to maximize their place in the Biosimilars market place. In addition, we have considerable experience litigating before the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission. Our attorneys have experience in all areas of Biotechnology, including: Aesthetic & Cosmetic Biotechnology Antibodies & Immunology Biofuels Biological Manufacturing Of Chemicals Biologics Diagnostic Tools Genomics Industrial Enzymes Peptides Personalized Medicine Research Tools & Reagents Stem Cells & Regenerative Medicine Synthetic Biology & Nanotechnology Therapeutics Tissue Engineering Transgenic Animals Vaccines